Entsar A Saad

Prof. Entsar A Saad

Damietta University, Damietta, Dumyāţ, Egypt
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Advances in Medical Sciences
Verified
Journal Article
Closed access
SHSalem A. Habib
Salem A. Habib
Entsar A SaadEntsar A Saad
Entsar A Saad
AEAshraf A. Elsharkawy
Ashraf A. Elsharkawy
ZAZeinab R. Attia
Zeinab R. Attia

3 January 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MSMayada I. Shosha
Mayada I. Shosha
FEFawzia Z. El-Ablack
Fawzia Z. El-Ablack
Entsar A SaadEntsar A Saad
Entsar A Saad
To shed light on the significance of thiazole derivatives in the advancement of cancer medication and to contribute to therapeutic innovation, we have designed the synthesis and antiproliferative activity investigation of 5-(1,3-dioxoisoindolin-2-yl)-7-(4-nitrophenyl)-2-thioxo-3,7-dihydro-2H-pyrano[2,3-d] thiazole-6-carbonitrile, the structure of thiazole derivative was confirmed by spectroscopic techniques UV, IR and NMR. The cytotoxic activity (in vitro) of the new hybrid synthesized compound on five human cancer cell lines; human liver hepatocellular carcinoma (HepG-2), colorectal carcinoma (HCT-116), breast adenocarcinoma (MCF-7), and epithelioid carcinoma (Hela), and a normal human lung fibroblast (WI-38) was studied using MTT assay. The compound exhibited a strong cytotoxicity effect against HepG-2 and MCF-7. The interaction of the newly synthesized compound with calf-thymus DNA (CT-DNA) was investigated at pH 7.2 by using UV–Vis absorption measurements, also, molecular docking was carried out to investigate the DNA binding affinity of the proposed compound with the prospective target, DNA (PDB ID: 1d12). Finally, molecular docking was carried out to examine the binding patterns with the prospective target, DNA-Topo II complex (PDB-code: 3QX3). Results indicated that the investigated compound strongly binds to CT-DNA via intercalative mode, and correlated with those obtained from molecular docking and in agreement with that of in vitro cytotoxicity activity.

1 March 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
Entsar A SaadEntsar A Saad
Entsar A Saad
MHMohamed M. Hassanien
Mohamed M. Hassanien
FEFaten W. El-Lban
Faten W. El-Lban

10 July 2019 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Shadia ElsayedShadia Elsayed
Shadia Elsayed
Entsar A SaadEntsar A Saad
Entsar A Saad
SMSahar I. Mostafa
Sahar I. Mostafa
Background: Due to the side effects of clinically approved anticancer drugs there is a great need to explore and develop new metal-based anticancer drug molecules of high efficiency with less or no side effects.Objective: To synthesize new metal complexes of 2-hydrazinobenzothiazole (hbt) and to investigate their potential anticancer characteristics.Methods: New five complexes; [VO(hbt)2SO4].4H2O (1), [Ru(hbt)2Cl3(H2O)] (2), [M(hbt)2Cl2] [M(II) = Pd (3), Pt (4)] and [Ag(hbt)2].NO3 (5) were prepared and their structure was investigated by means of FTIR, 1H NMR, ESI-MS and UV-Vis spectra, elemental and thermal analysis, magnetic and molar conductance measurements. The ligand and its complexes were examined as anticancer agents against Ehrlich ascites carcinoma (EAC) and human cancer cells (hepatocellular carcinoma Hep-G2, mammary gland breast cancer MCF-7 and colorectal carcinoma HCT-116). This feature is further supported by the DNAmetal complexes binding ability. In addition, anti-oxidation activity of the complexes was investigated.Results: Complex (5) shows the highest anticancer activity with IC50 of 5.15, 9.9, 13.1 and 17.7 µg/mL for EAC, HePG-2, MCF-7 and HCT-116, respectively. Complexes (2) and (3) show promising cytotoxicity against EAC and HePG-2 cells with IC50 5.49 and 16.2 µg/mL, respectively. While, complexes (1) and (4) show optimistic cytotoxicity against EAC with IC50 of 9.63 and 11.25 µg/mL, respectively. The order of DNA binding ability of the complexes is (5) > (3) > (2) > (1) > (4). Among the five complexes, complex (5) shows the best anti-oxidation activity.Conclusion: Complex (5) showed the highest DNA binding ability, anti-oxidation and anticancer activities.

1 June 2012 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
Entsar A SaadEntsar A Saad
Entsar A Saad

15 March 2017 in MedChemComm
Verified
Journal Article
Open access
PDF file
Entsar A SaadEntsar A Saad
Entsar A Saad
MHMohamed M. Hassanien
Mohamed M. Hassanien
HEHatem A. El-Mezayen
Hatem A. El-Mezayen
NENada M. Elmenawy
Nada M. Elmenawy
Cisplatin as a chief chemotherapy has nephro-toxicity and so we have tried to develop a novel antitumor drug based on a combination of cobalt metal ion with an organic moiety. The antitumor activity of the complex was tested in vitro and in vivo against murine Ehrlich ascites carcinoma (EAC). Antioxidant capacity and nucleic acids content were determined. Cobalt(II) diacetyl monoxime-2-hydrazinopyridine complex significantly diminished tumor load. It decreased the tumor proliferation rate and obviously increased the life span of EAC-bearing mice. It reversed the haematological parameters back towards normal, reduced liver enzymes and urea, and increased albumin and total protein. Antioxidant parameters levels were reversed towards normal. An assessment was conducted by comparing these results with those obtained using the standard drug, cisplatin. The results suggest that the cobalt complex can be considered as a potent anticancer agent as it showed appreciable antitumor activity in EAC-bearing mice that was almost analogous to that of the reference standard, cisplatin.